secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0000950170-21-003470
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharmaceuticals reports Q3 2021 cash of $296.5M, ORIC-101 early clinical data, and upcoming pipeline milestones
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.
- Initial Phase 1b data for ORIC-101 combo with enzalutamide showed safe profile and antitumor activity in 6 of 8 key patients.
- R&D expenses $12.9M (Q3 2021) vs $8.8M (Q3 2020); G&A expenses $5.6M vs $3.8M.
- Anticipated Q4 2021 milestones: initiate Phase 1 trial for ORIC-533 in multiple myeloma and file IND for ORIC-944.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/0000950170-21-003470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/oric-20211108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer